You are currently browsing the archives for 4 November 2017.
Displaying 1 - 2 of 2 entries.


PRESS RELEASE 9 February, 2015, Phoenix, AZ – Avella Specialty Pharmacy announced today that it’s been chosen by Pfizer among the limited sets of specialty pharmacies certified to distribute the producer’s breakthrough breasts cancer medication—Ibrance —which includes just received fast-tracked approval from the FDA . Ibrance will be utilized in the treating postmenopausal ladies with estrogen receptor – positive, human epidermal growth element receptor 2-adverse metastatic breast cancer who’ve not however received an endocrine-centered therapy. It really is to be utilized in conjunction with letrozole. Ibrance functions by inhibiting molecules involved with promoting the development of tumor cells.

AskBio enters patent permit agreement with Pfizer for HCV therapy Asklepios BioPharmaceutical.

HCV infection may be the most common chronic blood-borne an infection in the usa, with approximately 3. 2 million people chronically contaminated. ‘This license represents another example of AskBio‘s progress in the advancement and commercialization of gene-delivery platform technology that focuses on creating worth for a broad range of therapeutic options for patients, including those with HCV.’.. AskBio enters patent permit agreement with Pfizer for HCV therapy Asklepios BioPharmaceutical, Inc. , a privately-owned clinical-stage biotechnology company, announced today it offers entered right into a patent permit agreement with Pfizer, Inc.